Revenue Breakdown
Composition ()
No data
Revenue Streams
BioMarin Pharmaceutical Inc (BMRN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Voxzogo, accounting for 28.1% of total sales, equivalent to $218.39M. Other significant revenue streams include Vimizim and Naglazyme. Understanding this composition is critical for investors evaluating how BMRN navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, BioMarin Pharmaceutical Inc maintains a gross margin of 81.33%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6.02%, while the net margin is -3.96%. These profitability ratios, combined with a Return on Equity (ROE) of 9.07%, provide a clear picture of how effectively BMRN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BMRN competes directly with industry leaders such as RNA and TECH. With a market capitalization of $10.80B, it holds a significant position in the sector. When comparing efficiency, BMRN's gross margin of 81.33% stands against RNA's 100.00% and TECH's 66.37%. Such benchmarking helps identify whether BioMarin Pharmaceutical Inc is trading at a premium or discount relative to its financial performance.
